Skip to content

US · PBYI · BIOTECHNOLOGY

Puma Biotechnology, Inc. (PBYI) intrinsic value and stock valuation

$7.05as of 2026-11-21 · Mkt cap 406.69M

Data updated · price as of 2026-11-21

Strongly undervaluedIC value is more than 50% above the price. The exact IC value, upside and the fair-value band are available with Pro.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Puma Biotechnology, Inc. DCF and intrinsic value

InvestorsCraft values PBYI with the Chepakovich two-stage DCF model — currently rated strongly undervalued. How the model works · Run your own DCF prefilled from PBYI’s statements →

Puma Biotechnology, Inc. Graham Number

Graham Number: $6.04d — the price is above the Graham Number. Formula √(22.5 × EPS × BVPS) using the latest diluted EPS and book value per share. Guide · Calculator →

Healthcare · Biotechnology Los Angeles, CA 90024 pumabiotechnology.com

How the business is doing

Fiscal 2011–2025, USD

Revenue
$228.4M+0.3% 5y CAGRd
20112025
Net income
$31.1M
20112025
Free cash flow
$41.7M
20112025
Total equity
$130.3M
20112025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2011–2025, USD
20252024202320222021
Revenue$228.4M$230.5M$235.6M$228M$253.2M
Operating income$37.3M$31M$32.6M$23.7M$1.29M
Net income$31.1M$30.3M$21.6M$0.00-$-29.13M
EPSd$614.2K$616.7K$454K$0.00-$-716.78K
Operating cash flow$41.8M$38.9M$27M-$-15.83M$20.7M
Capital expenditure-$-70K-$-60K-$-12.64M-$-7M$0.00
Free cash flow$41.7M$38.9M$14.4M-$-22.83M$20.7M
Total assets$216.3M$213.3M$230.5M$222.1M$226.6M
Total debt$28.6M$74.1M$111.5M$114.3M$116.6M
Net debt-$-1.09M$4.86M$26.9M$38.1M$53.5M
Total equity$130.3M$92.1M$53.4M$21.6M-$-2.45M
Cash and short-term investments$97.5M$101M$95.9M$81.1M$82.1M
Income statement
20252024202320222021
Revenue$228.4M$230.5M$235.6M$228M$253.2M
Cost of revenue$58.2M$64.4M$62.7M$55.1M$63.7M
Gross profit$170.2M$166.1M$173M$172.9M$189.5M
Research and development expenses$62.1M$54.9M$50.4M$52.2M$71.9M
Selling, general and administrative expenses$71.2M$80.2M$89.3M$90M$116.3M
Other expenses-$-360K$0.00$620K$7M$0.00
Operating expenses$132.9M$135.1M$140.3M$149.2M$188.2M
Cost and expenses$191.1M$199.5M$203M$204.3M$251.9M
Interest income$4.08M$4.72M$2.6M$810K$160K
Interest expense$6.62M$12.5M$13.3M$11.6M$12.8M
Depreciation and amortization$10.9M$11.5M$11.5M$9.84M$11.3M
Ebitda$53.3M$48.1M$47.5M$21.9M-$-4.69M
Operating income$37.3M$31M$32.6M$23.7M$1.29M
Total other income/expenses, net-$-1.52M-$-6.87M-$-9.97M-$-23.26M-$-30.09M
Income before tax$35.8M$24.1M$22.7M$460K-$-28.8M
Income tax expense$4.67M-$-6.18M$1.08M$460K$320K
Net income$31.1M$30.3M$21.6M$0.00-$-29.13M
Weighted average shares outstanding$50M$48.7M$47.1M$44.7M$40.6M
Weighted average diluted shares outstanding$50.7M$49.1M$47.6M$44.9M$40.6M
Balance sheet
20252024202320222021
Cash and short-term investments$97.5M$101M$95.9M$81.1M$82.1M
Net receivables$53.7M$32M$48.5M$42.3M$32.5M
Inventory$5.51M$8.72M$7.08M$4.53M$7.11M
Total current assets$162.7M$147.7M$156.2M$134.3M$140M
Property, plant and equipment, net$5.56M$5.09M$8.65M$12.5M$15.8M
Goodwill and intangible assets$41.4M$51.1M$60.9M$70.6M$66.1M
Long-term investments$0.00$0.00$2.09M$0.00$0.00
Total non-current assets$53.6M$65.7M$74.3M$87.8M$86.6M
Total assets$216.3M$213.3M$230.5M$222.1M$226.6M
Accounts payable$5.06M$5.51M$6.89M$6.44M$11.2M
Short-term debt$23.8M$50.9M$38.8M$4.14M$3.57M
Deferred revenue$0.00$0.00$0.00$0.00$0.00
Total current liabilities$81.3M$96.1M$99.4M$77.5M$109.6M
Long-term debt$4.71M$23.2M$72.7M$110.1M$113.1M
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$4.71M$25.1M$77.7M$123M$119.4M
Capital lease obligations$6.02M$7.03M$11.8M$16M$19.6M
Total liabilities$86M$121.2M$177.1M$200.5M$229M
Common stock$10K$10K$10K$10K$0.00
Retained earnings-$-1.28B-$-1.31B-$-1.35B-$-1.37B-$-1.37B
Accumulated other comprehensive income (loss)$40K$10K-$0.00$0.00-$0.00
Total equity$130.3M$92.1M$53.4M$21.6M-$-2.45M
Total investments$67.9M$31.8M$13.5M$4.87M$19M
Total debt$28.6M$74.1M$111.5M$114.3M$116.6M
Net debt-$-1.09M$4.86M$26.9M$38.1M$53.5M
Cash flow statement
20252024202320222021
Net income$31.1M$30.3M$21.6M$0.00-$-29.13M
Depreciation and amortization$10.9M$11.5M$11.5M$9.84M$11.3M
Stock-based compensation$6.94M$8.24M$10.3M$11.8M$32.6M
Change in working capital-$-10.08M-$-3.54M-$-17.85M-$-44.5M-$-1.31M
Accounts receivable-$-21.28M$16.3M-$-8.37M-$-7.82M-$-5.98M
Inventory$3.21M-$-1.64M-$-2.55M$2.58M-$-3.65M
Accounts payable-$-450K-$-1.38M$450K-$-4.73M-$-900K
Net cash provided by operating activities$41.8M$38.9M$27M-$-15.83M$20.7M
Investments in property, plant and equipment-$-70K-$-60K-$-140K-$-7M$0.00
Acquisitions, net$0.00$0.00$0.00$0.00$0.00
Net cash used for investing activities-$-36.19M-$-20.44M-$-19.12M$7.1M-$-10.88M
Common stock issued$130K$150K$0.00$12.5M$0.00
Common stock repurchased$0.00$0.00$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities-$-45.2M-$-33.85M$0.00$12.2M-$-31.93M
Net change in cash-$-39.58M-$-15.37M$7.88M$3.5M-$-22.16M
Cash at end of period$31.7M$71.3M$86.7M$78.8M$75.3M
Operating cash flow$41.8M$38.9M$27M-$-15.83M$20.7M
Capital expenditure-$-70K-$-60K-$-12.64M-$-7M$0.00
Free cash flow$41.7M$38.9M$14.4M-$-22.83M$20.7M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Puma Biotechnology, Inc.

        Puma Biotechnology, Inc. is a biopharmaceutical company dedicated to the global development and commercialization of treatments aimed at advancing cancer care. Its lead drug candidate, orally administered neratinib (PB272), targets a range of indications. These include patients with early-stage HER2-overexpressed/amplified breast cancer, as well as adults suffering from advanced or metastatic HER2-positive breast cancer when used in combination with capecitabine. Furthermore, PB272 is being explored for solid tumors exhibiting HER2 mutations. The company holds a licensing agreement with Pfizer, Inc. for this drug and has established sub-licensing partnerships with Specialised Therapeutics Asia Pte Ltd., CANbridge BIOMED Limited, Pint Pharma International SA, Knight Therapeutics, Inc., Pierre Fabre Medicament SAS, and Bixink Therapeutics Co., Ltd. Established in 2010, Puma Biotechnology maintains its headquarters in Los Angeles, California.

        CEO
        Alan H. Auerbach
        Employees
        179
        Beta
        1.19

        Explore

        Frequently asked questions

        What is the intrinsic value of Puma Biotechnology, Inc. (PBYI)?

        Puma Biotechnology, Inc. (PBYI) is currently strongly undervalued based on the InvestorsCraft IC model — IC value is more than 50% above the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.

        Is PBYI undervalued?

        PBYI trades at a price of $7.05 (Nov 21, 2026): strongly undervalued — IC value is more than 50% above the price.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.